These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 28134915)
1. Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus. Wen X; Mousa JJ; Bates JT; Lamb RA; Crowe JE; Jardetzky TS Nat Microbiol; 2017 Jan; 2():16272. PubMed ID: 28134915 [TBL] [Abstract][Full Text] [Related]
2. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Corti D; Bianchi S; Vanzetta F; Minola A; Perez L; Agatic G; Guarino B; Silacci C; Marcandalli J; Marsland BJ; Piralla A; Percivalle E; Sallusto F; Baldanti F; Lanzavecchia A Nature; 2013 Sep; 501(7467):439-43. PubMed ID: 23955151 [TBL] [Abstract][Full Text] [Related]
3. Engineering, Structure and Immunogenicity of the Human Metapneumovirus F Protein in the Postfusion Conformation. Más V; Rodriguez L; Olmedillas E; Cano O; Palomo C; Terrón MC; Luque D; Melero JA; McLellan JS PLoS Pathog; 2016 Sep; 12(9):e1005859. PubMed ID: 27611367 [TBL] [Abstract][Full Text] [Related]
4. A Potent Neutralizing Site III-Specific Human Antibody Neutralizes Human Metapneumovirus Bar-Peled Y; Diaz D; Pena-Briseno A; Murray J; Huang J; Tripp RA; Mousa JJ J Virol; 2019 Oct; 93(19):. PubMed ID: 31292250 [TBL] [Abstract][Full Text] [Related]
5. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Swanson KA; Settembre EC; Shaw CA; Dey AK; Rappuoli R; Mandl CW; Dormitzer PR; Carfi A Proc Natl Acad Sci U S A; 2011 Jun; 108(23):9619-24. PubMed ID: 21586636 [TBL] [Abstract][Full Text] [Related]
6. Structural basis of respiratory syncytial virus neutralization by motavizumab. McLellan JS; Chen M; Kim A; Yang Y; Graham BS; Kwong PD Nat Struct Mol Biol; 2010 Feb; 17(2):248-50. PubMed ID: 20098425 [TBL] [Abstract][Full Text] [Related]
7. Human antibody recognition of antigenic site IV on Pneumovirus fusion proteins. Mousa JJ; Binshtein E; Human S; Fong RH; Alvarado G; Doranz BJ; Moore ML; Ohi MD; Crowe JE PLoS Pathog; 2018 Feb; 14(2):e1006837. PubMed ID: 29470533 [TBL] [Abstract][Full Text] [Related]
8. A Chimeric Pneumovirus Fusion Protein Carrying Neutralizing Epitopes of Both MPV and RSV. Wen X; Pickens J; Mousa JJ; Leser GP; Lamb RA; Crowe JE; Jardetzky TS PLoS One; 2016; 11(5):e0155917. PubMed ID: 27224013 [TBL] [Abstract][Full Text] [Related]
10. A novel pre-fusion conformation-specific neutralizing epitope on the respiratory syncytial virus fusion protein. Mousa JJ; Kose N; Matta P; Gilchuk P; Crowe JE Nat Microbiol; 2017 Jan; 2():16271. PubMed ID: 28134924 [TBL] [Abstract][Full Text] [Related]
11. Identification of antibody neutralization epitopes on the fusion protein of human metapneumovirus. Ulbrandt ND; Ji H; Patel NK; Barnes AS; Wilson S; Kiener PA; Suzich J; McCarthy MP J Gen Virol; 2008 Dec; 89(Pt 12):3113-3118. PubMed ID: 19008400 [TBL] [Abstract][Full Text] [Related]
12. Respiratory Syncytial Virus and Human Metapneumovirus Infections in Three-Dimensional Human Airway Tissues Expose an Interesting Dichotomy in Viral Replication, Spread, and Inhibition by Neutralizing Antibodies. Kinder JT; Moncman CL; Barrett C; Jin H; Kallewaard N; Dutch RE J Virol; 2020 Sep; 94(20):. PubMed ID: 32759319 [TBL] [Abstract][Full Text] [Related]
13. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein. Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590 [TBL] [Abstract][Full Text] [Related]
14. Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater Zhao M; Zheng ZZ; Chen M; Modjarrad K; Zhang W; Zhan LT; Cao JL; Sun YP; McLellan JS; Graham BS; Xia NS J Virol; 2017 Aug; 91(15):. PubMed ID: 28539438 [TBL] [Abstract][Full Text] [Related]
15. Characterization of potent RSV neutralizing antibodies isolated from human memory B cells and identification of diverse RSV/hMPV cross-neutralizing epitopes. Xiao X; Tang A; Cox KS; Wen Z; Callahan C; Sullivan NL; Nahas DD; Cosmi S; Galli JD; Minnier M; Verma D; Babaoglu K; Su H; Bett AJ; Vora KA; Chen Z; Zhang L MAbs; 2019; 11(8):1415-1427. PubMed ID: 31402751 [TBL] [Abstract][Full Text] [Related]
16. Structure, Immunogenicity, and Conformation-Dependent Receptor Binding of the Postfusion Human Metapneumovirus F Protein. Huang J; Chopra P; Liu L; Nagy T; Murray J; Tripp RA; Boons GJ; Mousa JJ J Virol; 2021 Aug; 95(18):e0059321. PubMed ID: 34160259 [TBL] [Abstract][Full Text] [Related]
17. Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein. Mousa JJ; Sauer MF; Sevy AM; Finn JA; Bates JT; Alvarado G; King HG; Loerinc LB; Fong RH; Doranz BJ; Correia BE; Kalyuzhniy O; Wen X; Jardetzky TS; Schief WR; Ohi MD; Meiler J; Crowe JE Proc Natl Acad Sci U S A; 2016 Nov; 113(44):E6849-E6858. PubMed ID: 27791117 [TBL] [Abstract][Full Text] [Related]
18. Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein. Bates JT; Keefer CJ; Slaughter JC; Kulp DW; Schief WR; Crowe JE Virology; 2014 Apr; 454-455():139-44. PubMed ID: 24725940 [TBL] [Abstract][Full Text] [Related]